Lv5
1370 积分 2022-06-08 加入
Semaglutide reduces the absolute risk of major cardiovascular events by 1.5%
4天前
已完结
Management of obesity in menopause
5天前
已完结
Weight loss between glucagon‐like peptide‐1 receptor agonists and bariatric surgery in adults with obesity: A systematic review and meta‐analysis
6天前
已完结
Association of Body Mass Index With Lifetime Risk of Cardiovascular Disease and Compression of Morbidity
7天前
已完结
Medically Supervised Weight Loss and Effects of Anti-Obesity Medications
10天前
已关闭
Effect of body mass index trajectory on lifetime risk of cardiovascular disease in a Chinese population: A cohort study
16天前
已完结
Obesity: A preventable, treatable, but relapsing disease
1个月前
已完结
Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Suboptimal Initial Clinical Response and Weight Gain Recurrence After Bariatric Surgery: a Systematic Review and Meta-analysis
1个月前
已完结
Dozens of new obesity drugs are coming: these are the ones to watch
1个月前
已完结
What Does the Rise of GLP-1 Drugs Mean for Bariatric Surgery?
1个月前
已完结
皖公网安备34019202002308
